Relapsing-Remitting Multiple Sclerosis (RRMS) may have a solution thanks to a revolutionary therapy that promises to reduce outbreaks by 67% for up to four years, according to Luciano Rossetti, VP of Merck Pharmaceuticals.
“It is a new oral therapy that has been shown to be effective in patients with RRMS (Relapsing-Remitting Multiple Sclerosis), helps to remit the disease and curbs its disabling effects without the need for continuous treatment or frequent follow-up,” said Luciano Rossetti from the Merck Pharmaceuticals.
Multiple sclerosis is a chronic, inflammatory, autoimmune disease in which the body’s immune system attacks myelin, an insulating coating around nerve cells in the brain and spinal cord, confusing it with an “intruder.” It is a hitherto incurable disease that affects more than 2.3 million people worldwide, 85% of whom have the Relapsing-Remitting Multiple Sclerosis.
Merck Pharmaceuticals has created a new therapy for multiple sclerosis known as Cladribine specifically for the treatment of people with acute RRMS, with frequent outbreaks and advanced disability. However, this drug won’t be available to all those affected by RRMS.
Merck Pharmaceutical developed an effective multiple sclerosis therapy
“This new treatment is considered a highly effective drug, as it significantly reduces the number of outbreaks and slows the progression of disability,” said Merck’s global director for development.
“One of the main effects of this disease is in the economic, as there are high costs associated with medications, relapses and the progression of disability,” Luciano Rossetti said.
It is estimated that 70% of multiple sclerosis cases occur between the ages of 20 and 40, which affects the quality of life of young adults in the most productive stage of their lives. Also, 25 % of patients will require a wheelchair 15 years after diagnosis. Also, Relapsing-Remitting Multiple Sclerosis can lead to disability and unemployment, as about 50% of patients with this disease lose their jobs between 3 and ten years after the installation of the illness.
Rossetti said the efficacy of this new treatment had been demonstrated in three clinical trials involving 2,700 patients.
The new multiple sclerosis therapy is contraindicated for pregnant women, people with chronic infection, such as tuberculosis or hepatitis, HIV, severe or moderate liver or kidney disease.